Maze Therapeutics Secures $115 Million Series D Funding to Advance Clinical-Stage Kidney Disease Programs

Funding:
Maze Therapeutics has completed a $115 million Series D financing round, co-led by Frazier Life Sciences and Deep Track Capital, with participation from Janus Henderson Investors and Logos Capital, among other existing investors1.

Programs:
The funding will support the advancement of Maze's lead programs, MZE829 and MZE782. MZE829 is an oral APOL1 inhibitor for APOL1 kidney disease (AKD), and MZE782 is an oral SLC6A19 inhibitor for chronic kidney disease (CKD) and phenylketonuria (PKU)1 2 3.

Clinical Trials:

MZE829:
Positive Phase 1 data in healthy volunteers showed MZE829 was well-tolerated, with a half-life supporting once-daily dosing. A Phase 2 trial is expected to begin in the first quarter of 20252 4.

MZE782:
The Phase 1 trial in healthy volunteers is ongoing, with initial results, including potential proof of mechanism, anticipated in the second half of 20253.

Disease Impact:

APOL1 Kidney Disease (AKD):
Affects approximately one million individuals of West African ancestry in the U.S., with genetic variants G1 and G2 linked to increased risk of progressive kidney diseases2 5.

Chronic Kidney Disease (CKD):
Impacts approximately 37 million individuals in the U.S., with current treatments focusing on slowing disease progression rather than addressing the underlying cause3 5.

Platform:
Maze Therapeutics uses its proprietary Compass platform to identify genetic variants and biological pathways driving disease in specific patient groups, enabling the development of novel precision medicines1 2 3.